Key Points
- Director Erika Nardini sold 198 shares on March 17 at an average price of $506.58 for about $100,303, reducing her stake by ~9.24% to 1,946 shares (SEC Form 4 filed).
- Axon beat quarterly estimates with EPS of $2.15 vs. $1.60 and revenue of $796.7M vs. $755.3M (revenue +38.5% YoY), while the stock traded down ~2% to $498.46 and sits in a one-year range of $396.41–$885.91.
- Analyst and institutional backdrop is mixed but tilted positive: 16 Buy vs. 3 Hold ratings (average target $762.93) and recent institutional buying contrast with some target cuts and near-term price pressure amid insider selling.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) Director Erika Nardini sold 198 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the transaction, the director directly owned 1,946 shares in the company, valued at $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Axon Enterprise Trading Down 2.0%
Shares of NASDAQ AXON traded down $9.95 during midday trading on Thursday, reaching $498.46. The company had a trading volume of 21,874 shares, compared to its average volume of 996,109. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The firm's fifty day moving average price is $524.40 and its 200-day moving average price is $603.77. The stock has a market cap of $40.08 billion, a PE ratio of 328.99, a price-to-earnings-growth ratio of 10.81 and a beta of 1.46.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.Axon Enterprise's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period last year, the company earned $2.08 EPS. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.
Institutional Trading of Axon Enterprise
Large investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. raised its holdings in Axon Enterprise by 53.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company's stock worth $6,542,000 after purchasing an additional 4,002 shares in the last quarter. World Investment Advisors boosted its stake in shares of Axon Enterprise by 37.1% during the 4th quarter. World Investment Advisors now owns 1,035 shares of the biotechnology company's stock valued at $588,000 after purchasing an additional 280 shares in the last quarter. Pure Financial Advisors LLC increased its position in shares of Axon Enterprise by 6.7% during the fourth quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company's stock valued at $207,000 after buying an additional 23 shares during the period. Tobam increased its position in shares of Axon Enterprise by 17.3% during the fourth quarter. Tobam now owns 5,833 shares of the biotechnology company's stock valued at $3,313,000 after buying an additional 859 shares during the period. Finally, Clearwave Capital LLC bought a new position in Axon Enterprise in the fourth quarter worth about $325,000. Institutional investors own 79.08% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. Needham & Company LLC decreased their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a "buy" rating on the stock in a research note on Friday, February 20th. Weiss Ratings reissued a "hold (c-)" rating on shares of Axon Enterprise in a report on Monday, December 29th. Northcoast Research upgraded shares of Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 price objective on the stock in a research report on Tuesday, January 6th. Barclays lowered their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an "overweight" rating for the company in a research note on Wednesday, February 25th. Finally, Craig Hallum reissued a "buy" rating and issued a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $762.93.
Read Our Latest Report on Axon Enterprise
Key Stories Impacting Axon Enterprise
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Software & services momentum — Analysts and coverage pieces highlight AXON’s strong Software & Services growth (nearly +40% in 2025) and rising subscription revenue, which supports a higher-margin recurring-revenue outlook that investors favor. Axon's Software & Services Strength in Focus
- Positive Sentiment: Municipal funding adoption — A Decatur, IL city council grant ($1.97M) to upgrade police department tech suggests continued municipal demand for public-safety solutions (a core Axon end-market). Local grants and procurement activity tend to support hardware + software contract growth. Decatur City Council accepts $1.97M grant
- Positive Sentiment: Institutional interest cited — Coverage pointing to money-manager interest (Baron Opportunity Fund mention) and “trending” status can attract new retail/institutional attention and bolster liquidity/coverage. What Makes Axon Enterprise a Lucrative Investment?
- Neutral Sentiment: “Trending” stories and analyst rundowns — Multiple aggregator pieces (Zacks, Yahoo) are flagging AXON as a widely searched/trending stock; useful for awareness but not a direct fundamental catalyst. AXON Is a Trending Stock
- Neutral Sentiment: Short-interest data appears unreliable — Recent short-interest posts show “0 shares” and NaN changes with a 0.0 days-to-cover, which reads like a reporting glitch rather than actionable short-seller pressure. Treat this as noisy/unchanged until clarified by exchanges/brokers.
- Negative Sentiment: Insider selling — Director Erika Nardini sold 198 shares at ~$506.58 (SEC Form 4 filed), reducing her stake ~9.2%. Insider sales can be perceived negatively by investors even if small in absolute terms. SEC Form 4 — Nardini sale
- Negative Sentiment: Near-term price pressure / market skepticism — A Forbes piece highlights a 6-day losing streak and a roughly $6.7B market-cap decline over that span, feeding sentiment that Axon’s near-term growth premium may be under pressure. That narrative likely contributes to today’s downward price move. Is Axon Stock's Growth Story Over?
About Axon Enterprise
(
Get Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
